Talk:Drug repositioning

I noticed that the latest changes to this entry have reduced its informative value and neutral character.

In the original version of the article, I had included the External Links information, which I found very useful. These included companies and other organizations active in this space.

The recent edits have removed these External Links but introduced in the second paragraph Ore Pharmaceuticals. In this way a subtle but blatant bias has been introduced that should be redressed. Keep in mind that Ore Pharmaceuticals was mentioned in the External links section.

I therefore propose to reinstate the External Links section and also remove the reference to Ore in the running text.

Xtisths (talk) 15:49, 14 November 2008 (UTC)

Evidence
I think that we should have a section on the available evidence from systemic reviews on repurposed drugs. There is for instance a cochrane review on the use of cimetidine in colon cancer though the findings are murky: "Given the variability amongst the trials the results can only be considered as speculative, as opposed to strong evidence for this approach." I'm certain there are other good meta analysis. Chickpecking (talk) 23:07, 7 December 2017 (UTC)

Lead
I think the lead would be more straightforward if it were written as:

Drug repositioning (also known as drug repurposing, re-profiling, re-tasking or therapeutic switching) is the repurposing of an approved drug for the treatment of another disease or medical condition.

The "treat new indications" part sounds odd IMO. Just my 2¢.  Seppi  333  (Insert 2¢) 03:13, 14 May 2018 (UTC)


 * way yes. meant to do that and didn't...disease and medical condition to go the same page btw. Jytdog (talk) 03:35, 14 May 2018 (UTC)